Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing
Pp. 61-104 (44)
Omobolanle Janet Jesumoroti, Faith Akwi and Paul Watts
A number of new antiviral drugs have made HIV/AIDS a manageable
disease by the introduction of integrase strand transfer inhibitors. One of the major
concerns is the accessibility of these drugs in lower income countries. Thus, adequate
supplies and cost effective syntheses of these drugs via flow technology are of great
importance. Presently, there are four integrase strand transfer inhibitors approved by
FDA. This chapter will focus on the published synthesis of currently FDA approved
integrase inhibitor drugs and other HIV drugs developed through flow technology.
Thus hoping that such a review could be useful to scientists and academia desiring a
greater understanding of HIV integrase drug development at reduced cost and could
serve as a context for further research and possible collaboration with the industry.
Active pharmaceutical intermediate, Batch synthesis, Continuous
flow synthesis, Food and drug administration, HIV/AIDS, HIV integrase, HIV
protease, Integrase strand transfer inhibitor, Microreactors, Process development.
Nelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.